Amerikanische Gesellschaft für Hirudotherapie

Culture-independent characterization of the digestive-tract microbiota of the medicinal leech reveals a tripartite symbiosis

Microbiology article published in Applied and Environmental Microbiology (2006)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikWorthen PL, Gode CJ, Graf J · Applied and environmental microbiology, 2006

Abstract

Culture-based studies of the microbial community within the gut of the medicinal leech have typically been focused on various Aeromonas species, which were believed to be the sole symbiont of the leech digestive tract. In this study, analysis of 16S rRNA gene clone libraries confirmed the presence of Aeromonas veronii and revealed a second symbiont, clone PW3, a novel member of the Rikenellaceae, within the crop, a large compartment where ingested blood is stored prior to digestion. The diversity of the bacterial community in the leech intestinum was determined, and additional symbionts were detected, including members of the alpha-, gamma-, and delta-Proteobacteria, Fusobacteria, Firmicutes, and Bacteroidetes. The relative abundances of the clones suggested that A. veronii and the novel clone, PW3, also dominate the intestinum community, while other clones, representing transient organisms, were typically present in low numbers. The identities of these transients varied greatly between individual leeches. Neither time after feeding nor feeding on defibrinated blood caused a change in identity of the dominant members of the microbial communities. Terminal restriction fragment length polymorphism analysis was used to verify that the results from the clone libraries were representative of a larger data set. The presence of a two-member bacterial community in the crop provides a unique opportunity to investigate both symbiont-symbiont and symbiont-host interactions in a natural model of digestive-tract associations.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.
Indexed MeSH termsAnimalsBacteriaDNA, BacterialDNA, RibosomalGastrointestinal TractGenes, rRNALeechesMolecular Sequence DataPhylogenyPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthRNA, Ribosomal, 16S

Zusammenfassung

16S rRNA gene clone libraries reveal a tripartite symbiosis dominated by Aeromonas veronii and a novel Rikenella-like bacterium (PW3) in the crop, with diverse low-abundance transient organisms in the intestinum.

Warum dies für die Hirudotherapie relevant ist

This study used culture-independent 16S rRNA gene clone libraries and terminal restriction fragment length polymorphism analysis to characterize the digestive-tract microbiota of the medicinal leech, confirming Aeromonas veronii and revealing a second dominant symbiont, clone PW3 (a novel Rikenellaceae member), in the crop, with additional transient low-abundance organisms in the intestinum. Neither time after feeding nor defibrinated blood changed the dominant community members. For ASH, this is directly relevant as it refines understanding of the medicinal leech's core microbiome, informing both symbiosis biology and infection-risk considerations. The caveat is that this is an animal/molecular study of leech microbiology with no human clinical component or therapeutic outcomes.

Zitation

Culture-independent characterization of the digestive-tract microbiota of the medicinal leech reveals a tripartite symbiosis.

Worthen PL, Gode CJ, Graf J · Applied and environmental microbiology, 2006

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.